<DOC>
	<DOCNO>NCT02514447</DOCNO>
	<brief_summary>This study investigate potential clinical benefit trilaciclib ( G1T28 ) preserve bone marrow immune system , enhance chemotherapy antitumor efficacy administer prior topotecan patient previously treat extensive-stage SCLC . The study consist 2 part : limited open-label , dose-finding portion ( Part 1 ) , randomize double-blind portion ( Part 2 ) . Both part include 3 study phase : Screening Phase , Treatment Phase , Survival Follow-up Phase . The Treatment Phase begin day first dose study treatment complete Post-Treatment Visit . The open-label portion enrol 32 patient randomized portion enroll approximately 60 patient .</brief_summary>
	<brief_title>Trilaciclib ( G1T28 ) , CDK 4/6 Inhibitor , Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Male female subject age â‰¥18 year Unequivocally confirm diagnosis SCLC histology cytology , preferably include presence neuroendocrine feature immunohistochemistry Progression prior first secondline chemotherapy eligible receive topotecan therapy At least 1 target lesion measurable RECIST , Version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Adequate organ function Presence symptomatic brain metastasis require immediate treatment radiation therapy steroid . Uncontrolled ischemic heart disease uncontrolled symptomatic congestive heart failure Known history stroke cerebrovascular accident within 6 month prior enrollment Other uncontrolled serious chronic disease condition investigator 's opinion could affect compliance followup protocol Concurrent radiotherapy site radiotherapy within 2 week prior enrollment previous radiotherapy target lesion site ( site follow determination response ) Receipt investigational medication within 2 week prior enrollment History topotecan treatment SCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SCLC</keyword>
</DOC>